NAD
NAD+
Not a peptide. A dinucleotide coenzyme: nicotinamide mononucleotide joined to adenosine monophosphate through a pyrophosphate bridge. It is a substrate and a redox carrier rather than a receptor ligand, cycling between oxidised and reduced forms in central metabolism and serving as the substrate consumed by sirtuins, PARP enzymes and CD38.
NAD+ has 71 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 7,763 planned or enrolled participants across the 70 studies that published a figure. No FDA-approved product contains NAD+. 15,777 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names NAD+; the registry search is fuzzy, so every match is re-checked. None of this says whether NAD+ works or is safe.
FDA status
Research only
Human studies
71
Furthest phase
Phase 4
Papers, 10 yr
15,777
Readership
19,297
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
71
Registered human studies
Phase 4
Furthest phase reached
7,763
Planned or enrolled participants, across 70 studies that published a figure
None
No FDA-approved product contains it
260 loose registry matches were checked and 71 confirmed — 189 named something else and were discarded. We count a study only when NAD+ is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What NAD+ is, and what it has been studied for
NAD+ is classified by ChEMBL as a small molecule, and appears in trial registrations under NSC-20272.
Across 71 registered trials, it has been studied in Aging, Parkinson Disease, Healthy Aging and Covid19. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Haukeland University Hospital and National Heart, Lung, and Blood Institute (NHLBI) among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
NAD+ reached Phase 4 across 71 registered trials.
No FDA-approved product contains NAD+. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying NAD+?
Papers published each year that name NAD+ in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 1471 | 0 | Yes |
| 2018 | 1517 | 0 | Yes |
| 2019 | 1620 | 0 | Yes |
| 2020 | 1734 | 0 | Yes |
| 2021 | 1825 | 1 | Yes |
| 2022 | 1865 | 1 | Yes |
| 2023 | 1794 | 3 | Yes |
| 2024 | 1897 | 3 | Yes |
| 2025 | 2140 | 2 | Yes |
| 2026 | 1616 | 1 | No |
15,777 papers and 11 registered trials between 2017 and 2026. A paper counts when “NAD+” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on NAD+
15,777 indexed papers name NAD+ in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- NAD(+) metabolism and its roles in cellular processes during ageing
- NAD+ and sirtuins in aging and disease
- NAD(+) homeostasis in health and disease
- NAD(+) metabolism, stemness, the immune response, and cancer
- NAD metabolism: Role in senescence regulation and aging
- Evolving concepts in NAD(+) metabolism
- Regulation of and challenges in targeting NAD(+) metabolism
- NAD(+) homeostasis in human health and disease
Collected 2026-08-02from PubMed, phrase-matched on “NAD+” in title and abstract. Run the same search.
About NAD+
Not a peptide. A dinucleotide coenzyme: nicotinamide mononucleotide joined to adenosine monophosphate through a pyrophosphate bridge. It is a substrate and a redox carrier rather than a receptor ligand, cycling between oxidised and reduced forms in central metabolism and serving as the substrate consumed by sirtuins, PARP enzymes and CD38.
- Also known as
- Nicotinamide adenine dinucleotide · NAD
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.